Published data have reported that components of the peripheral blood are significant prognostic factors in hematologic and solid malignancies. Thus, we sought to investigate if the preoperative absolute lymphocyte count (ALC) and absolute monocyte count (AMC) affects disease progression and survival after complete surgical resection of advanced malignant melanoma.
A dvanced malignant melanoma remains a major source of mortality despite recent advances in treatment. In the United States, approximately 9400 individuals will die from malignant melanoma in 2013 (1.6% of cancer-related deaths). 1 Current prognostic factors are based on the American Joint Committee on Cancer (AJCC) 7th edition TNM staging system, which incorporates information about the primary tumor thickness, presence of ulceration, number of lymph nodes affected, and distant sites of metastases. 2 Melanoma progression and subsequent distant spread are believed to be at least in part regulated by host immunity (tumor microenvironment, [3] [4] [5] [6] the sentinel lymph node, 7 and systemically 8 ). Interestingly, despite the recognition of the relevance of the immune system in melanoma biology, there is currently no routine use of biomarkers to reflect a host's immune response to cancer.
An inexpensive and clinically utilized estimate of systemic immunity in humans is the absolute concentration of peripheral blood lymphocytes. The absolute lymphocyte count (ALC) at the time of diagnosis has been identified as an independent prognostic factor for survival in multiple hematologic malignancies, [9] [10] [11] [12] and some solid tumors. 13 Similarly, the absolute monocyte count (AMC), another peripheral blood biomarker of immune competence, has also been reported as a negative prognostic factor in several cancers. 11, 12, 14, 15 In melanoma, both ALC and AMC seem to impact clinical outcomes in patients with unresectable disseminated metastatic melanoma who have been treated with immunotherapy. 14, 16 In these studies, patients with normal or increased lymphocyte count and decreased monocyte count in the peripheral blood seem to have better clinical outcomes relative to those that do not. In this same regard, patients that are able to undergo surgical resection of all metastatic disease can also experience excellent outcomes, despite no additional therapy. However, the prognostic significance of preoperative ALC or AMC in resectable melanoma has not been studied. An inexpensive biomarker of immune competence may improve patient selection for metastectomy and adjuvant therapy. Thus, we postulate that immune competence may play an important role in the clinical outcomes of patients undergoing complete surgical resection of advanced melanoma. Therefore, we conducted a retrospective study to assess the prognostic significance of preoperative ALC and AMC, in patients with resected advanced melanoma.
MATERIALS AND METHODS

Study Population
Patients with complete resected stage III or stage IV melanoma who were followed at Mayo Clinic, Rochester, Minnesota from 2000 through 2010 were considered for study participation. All study subjects had a pathology report available for review, with confirmation of melanoma. Staging was assigned based on the AJCC 7th edition TNM staging system. 2 The stage III cohort included patients with an initial diagnosis of stage III, as well as patients that had for the first time a locoregional recurrence. Of the 246 eligible patients for the study, 19 patients were excluded for the following reasons: 4 had a history of organ transplant and were taking several immunosuppressive therapies, 3 had a diagnosis of pancytopenia, 2 were in chronic immunosuppressive treatment for an autoimmune disease, and 10 patients had a concomitant malignant diagnosis, such as lymphoma or pancreatic cancer. Thus, our study sample included 227 evaluable patients (153 stage III and 74 stage IV) who had undergone complete resection of all clinically or radiologically evident disease. For patients with multiple resections, only the first date of resection was used. Demographic, clinical, and pathologic data were collected and managed using REDCap electronic data capture tools hosted at the Mayo Clinic. 17 All patients had previously given consent for their medical record to be reviewed. Study approval was obtained from the Mayo Clinic Institutional Review Board.
End Points
The primary endpoint for this study was to determine the prognostic significance of the preoperative ALC and AMC values in patients undergoing complete surgical resection of high-risk melanoma with respect to relapse-free survival (RFS) and overall survival (OS). The ALC and AMC were obtained from a standardized complete blood count before surgical resection. The secondary endpoint was to determine whether the ALC and AMC before complete resection of stage III/IV disease was an independent prognostic factor for RFS and OS in melanoma patients. RFS was measured from the date of surgery to the date of relapse, death, or last follow-up. OS was measured from date of surgery to the date of death or last follow-up.
Statistical Analysis
Continuous variables were summarized with means, SDs, and ranges; whereas categorical variables were summarized with frequency counts and percentages. A separate analysis was performed for the stage III and stage IV cohorts, due to heterogeneity in the extent of disease. RFS and OS were estimated using the Kaplan-Meier method. Differences in survival curves were tested for statistical significance using the 2-tailed log-rank test. The ALC and AMC were analyzed as both continuous and dichotomized variables. The optimal cutoff point for each cohort (stage III and stage IV) was based on the w 2 from the long-rank statistics that yielded the greatest difference in survival of RFS and OS, when analyzing different cutoff points from the interquartile range (25th to 75th) for the presurgical ALC and AMC. The Cox proportional hazards model was used for the univariate and multivariate analysis to evaluate the ALC and AMC as prognostic factors for RFS and OS. All prognostic factors with a P-value < 0.2 in the univariate analysis were included in the multivariate analysis. P-values were not adjusted for multiple comparisons. All tests were 2-sided and P-values < 0.05 were considered statistically significant.
RESULTS
Patients Characteristics
A total of 227 patients who had undergone complete resection of their metastatic melanoma (153 stage III and 74 stage IV) qualified for the study ( Table 1 ). The median age at the time of resection for patients with stage III melanoma was 59 years (range, 18 to 88 y). Of these, 63% of patients were men. The median follow-up for this group was 30 months (range, 2 to 126 mo). The median age at time of resection for the 74 patients with stage IV metastatic melanoma was 56 years (range, 26 to 91 y) and 69% were male. The median follow-up for this cohort was 24 months (range, 2 to 117 mo). In terms of previous treatment, 31% had received granulocytemacrophage colony-stimulating factor, 12% had received prior interferon-a, 4% had participated in a vaccine trial, and 4% had received prior chemotherapy. The majority of patients with stage IV disease had only 1 distant metastatic lesion (85%), with only 14% having 2 organs involved and only 1 patient (1%) had 3 organs involvement. Additional patient characteristics are summarized in Table 1 .
RFS and OS for Stage III Resected Melanoma
There was no significant relationship between the preoperative ALC, as a continuous or dichotomous variable, in resected stage III melanoma with RFS and OS ( Table 2 ). The AMC was not significantly associated with RFS; however, increasing AMC was significantly associated with a worse OS (P < 0.04). The AMC was also analyzed as a dichotomous variable. The choice of cutoff for the AMCZ0.6Â10 9 /L was supported by the data based on the w 2 value (w 2 = 6.37, P < 0.01), using the log-rank test analysis for different cutoff points between the 25% and 75% quartile values (0.62 to 0.43Â 10 9 /L). A preoperative AMCZ0.6Â10 9 /L was associated with inferior OS on univariate analysis (HR = 1.89, P < 0.01) ( Table 2) . We next examined the RFS and OS curves stratified by the AMC for visual representation (Figs. 1A and B, respectively). Although the RFS curve for stage III melanoma patients with an AMC < 0.6Â10 9 /L versus Z0.6Â10 9 /L was statistically significant ( Fig. 1A) , it failed to show prognostic significance as a continuous variable in the univariate analysis. In the OS curve ( Fig. 1B) , a preoperative AMCZ0.6Â10 9 /L (n = 51) was associated with an inferior survival when compared with patients with an AMC < 0.6Â10 9 /L (n = 102) (median OS: 34.8 vs. 63.9 mo, respectively, P < 0.008). The difference in survival curves when stratified by ALC was not statistically significant (Figs. 1C, D).
Additional prognostic factors were examined in univariate analysis as indicated in Table 2 . Age (continuous variable), sex, Breslow thickness (continuous variable), and number of positive lymph nodes (< 4 vs. Z4) were significant predictors of RFS and OS in the univariate analysis. All prognostic factors with a P-value < 0.2 were included in the multivariate analysis with both ALC and AMC as binary variables. As summarized in Table 2 , sex, Breslow thickness, and positive lymph nodes Z4 were independently significant prognostic factors for RFS. The AMCZ0.6 Â10 9 /L and positive lymph nodes Z4 remained independent predictors of OS on multivariate analysis.
RFS and OS for Stage IV Resected Melanoma
The relationship between preoperative AMC (continuous variable) and RFS, approached, but did not reach statistical significance (P < 0.08). Similarly, AMC as a continuous variable was not significantly associated with OS (P < 0.84). In contrast, the preoperative ALC as a continuous variable was significantly associated with RFS (P < 0.008), whereas the relationship between ALC and OS did not reach statistical significance (P < 0.20) (Table 3 ). The preoperative ALC was dichotomized into <1.9Â10 9 /L and Z1.9 Â10 9 /L. This cutoff point was supported by the data and based on the w 2 value (w 2 = 7.67, P < 0.0056) analyzed at different cutoff points between the 25% and 75% quartiles (1.1 to 1.9Â10 9 /L), from the log-rank test. Patients with an ALCZ1.9 Â10 9 /L (n = 26) experienced a superior median RFS compared with patients with an ALC < 1.9Â 10 9 /L (n = 48) (median RFS: 11.4 vs. 5.4 mo, respectively, P < 0.006) ( Fig. 2A ). However, an ALCZ1.9Â 10 9 /L was not associated with superior OS when compared with the group with an ALC < 1.9 Â10 9 /L (median OS: 51.3 vs. 33 mo, respectively, P = 0.16) ( Fig. 2B ). An ALCZ1.9Â 10 9 /L was associated with an estimated 3-year OS of 65% (95% confidence interval, 44%-82%). In contrast, an ALC < 1.9Â 10 9 /L had an estimated 3-year OS of 38% (95% confidence interval, 24%-54%). There was no statistically significant difference in survival curves when stratified by AMC (Figs. 2C, D) .
ALC (binary and continuous) and AMC (binary and continuous), as well as other significant factors such as age (continuous variable), sex, Breslow thickness (continuous variable), prior systemic therapy (yes or no), disease-free interval before presentation with distant metastasis (continuous variable), adjuvant therapy (yes or no), number of metastatic sites (1 or >1), and the presence of intervening regional disease (yes or no) were examined in univariate analysis. As demonstrated in Table 3 , besides the ALC, age was the other significant factor in univariate analysis for RFS. None of the factors were significant on univariate analysis for OS. The multivariate model accounted for age, Breslow thickness, preoperative AMCZ0.6 Â10 9 /L, adjuvant therapy, and preoperative ALC < 1.9 Â10 9 /L. As summarized in Table 3 , only ALC was an independent prognostic factor for RFS, with over a 2-fold decrease in RFS for ALC < 1.9 Â10 9 /L (HR = 2.22; 95% confidence interval, 1.07-4.88; P < 0.03). zDefined as appearance of regional lymph nodes or in-transit metastases after diagnosis of primary melanoma, but before diagnosis of stage IV disease.
GM-CSF indicates granulocyte-macrophage colony-stimulating factor; IFN, interferon.
DISCUSSION
Our study is the first to demonstrate the prognostic value for the preoperative ALC and AMC for survival in completely resected advanced melanoma. The ALC and AMC are inexpensive markers of systemic immunity that can be utilized in clinical practice to select appropriate candidates for resection of metastatic melanoma and to guide adjuvant therapies. Our data suggests that the AMC may have an immune-regulatory function in locally advanced melanoma, as an AMCZ0.6 Â 10 9 /L is strongly associated with poor OS in stage III FIGURE 1. A, Relapse-free survival (RFS) curves for stage III malignant melanoma stratified by preoperative absolute monocyte count (AMC). B, Overall survival (OS) curves for stage III malignant melanoma stratified by preoperative AMC. C, RFS curves for stage III malignant melanoma stratified by preoperative absolute lymphocyte count (ALC). D, OS curves for stage III melanoma stratified by preoperative ALC. 2 . A, Relapse-free survival (RFS) curves for stage IV malignant melanoma stratified by preoperative absolute lymphocyte count (ALC). B, Overall survival (OS) curves for stage IV malignant melanoma stratified by preoperative ALC. C, RFS curves for stage IV malignant melanoma stratified by preoperative absolute monocyte count (AMC). D, OS curves for stage IV melanoma stratified by preoperative AMC. melanoma patients. In contrast, a higher preoperative ALC is associated with superior RFS in patients with more advanced melanoma (stage IV), both as a continuous and as dichotomous variable. This marker may be a useful tool to stratify patients who are at higher risk of recurrence at time of surgical resection. More importantly, these associations remained significant when controlling for other known clinical and pathologic factors.
The role of the host immune status is crucial in the understanding of the natural history and biology of malignant melanoma. Immunotherapy is of great interest for the treatment of advanced melanoma, with reports of improved OS in patients treated with ipilimumab, which potentiates an antitumor T-cell response, but at the cost of severe side effects. 18 Moreover, autoimmunity, as measured by autoantibodies and autoimmune manifestations, has been associated with prolonged survival in patients with melanoma receiving adjuvant immunotherapy as reported by Gogas et al. 8 A survival benefit has also been reported in patients with metastatic melanoma receiving immunotherapy that develop vitiligo (an autoimmune disease). 19 This is further evidence of the significance of host immunity and the role in the outcomes of melanoma.
To our knowledge, this is the first study describing ALC as a prognostic indicator of relapse after surgical resection of metastatic melanoma. The prognostic significance of the ALC is well established in several hematologic malignancies, as well as solid tumors, either at time of diagnosis or after autologous stem cell transplant. 9, 10, [20] [21] [22] [23] [24] [25] [26] Similarly, other authors have reported the prognostic role of the ALC in malignant melanoma; however, the patient population in these studies was very different from ours, as they looked at patients receiving immunotherapy. One study reported superior OS in patients with metastatic melanoma who had an ALCZ1000 cells/mL after 2 ipilimumab treatments. 16 However, this study had several differences from ours, which may explain why we detected a superior RFS in patients with a high ALC, but were not able to identify ALC as predictive marker for OS. First, the patient population of this study consisted on unresectable stage III/IV, which by definition has extensive disease not amenable for surgical resection. This is a key factor as it has been reported that patients with resectable stage IV melanoma have a median OS of approximately 21 27 versus 6.2 months 28 for patients with unresected stage IV melanoma. This illustrates that the extent of disease burden is not equivalent in the study by Ku et al 16 when compared with ours, hence the differences in ALC predictive value for OS. Second, the predictive value of the ALC was assessed during treatment with ipilimumab in the Ku study, 16 whereas we were interested in the predictive value of ALC before surgical resection of metastatic disease. Other studies have investigated peripheral blood lymphocyte subsets in patients with metastatic melanoma, reporting improved survival in patients with an increased CD4 + / CD8 + ratio at the beginning of chemoimmunotherapy. 29, 30 Similarly, a statistically significant correlation has been reported between the occurrence of CD4 + lymphocytes in metastatic lesions and therapeutic benefit of interferon-a in melanoma patients with regional and metastatic disease. 6 Further supporting the theory that the host's immune system is a key player in the antitumor response, it has been reported that increased tumorinfiltrating lymphocytes in lymph node melanoma metastases have superior survival. 31, 32 The preoperative AMC was an independent factor that influenced OS after surgical resection of tumors in stage III patients, and we hypothesized that this is due to the effect of monocytes on immunosuppression. Previous studies have suggested several mechanisms by which the peripheral blood monocytes might influence cancer progression. Some investigators have shown that the immunosuppressive cytokine IL-10 is produced mainly by monocytes in melanoma patients, and that IL-10 levels are inversely correlated with survival. 33 Other investigators have shown that the presence of marker CD163 in serum of patients with stage I/II melanoma is associated with poor OS. 34 Consistent with our results regarding monocytes and relapse of disease, there is a lack of association between serum CD163 and progression-free survival. 34 The scavenger receptor CD163 is expressed on circulating monocytes and tissue macrophages, and is associated with anti-inflammatory mediators that promote tumor growth and metastases. 35, 36 The different results we report in this study between patients with stage III and stage IV disease may be due to several factors. First, stage III melanoma patients have regional disease, which is still limited to the area of the primary tumor and its lymphatic drainage. The patients in this cohort may have not yet developed any serious shift of the lymphocytes in their peripheral blood. However, stage IV patients have distant disease that has propagated beyond the original tumor, affecting distant organs. This may explain the difference in the predictive value of preoperative ALC in stage III and stage IV patients. The AMC was a predictive factor for OS in stage III patients, and, however, it failed to show prognostic significance in stage IV patients. As described before, the localized nature of stage III disease may provide a niche for migration of monocytes, before a full-blown systemic effect is noted.
The study has several weaknesses, including the small sample size and limited power to detect statistical differences. However, given the retrospective nature of this study, we cannot change our patient number. Another limitation is that we were not able to include serum LDH level in the statistical model, which is a known prognostic factor, because it was not available for the majority of the patients included in this study. We recognize the importance of serum LDH in the prognosis of stage IV patients and encourage future prospective studies to collect information on this variable.
Our data suggests that advanced melanoma has a different immune response between regional metastatic disease and distant disease, hence the difference in predictive role of the ALC and AMC in stage III and stage IV disease. The study showed better RFS in patients with resected stage IV melanoma who presented with higher ALC before surgical resection of the metastatic lesions, suggesting an important role of the host immunity in this group of patients. However, the preoperative AMC in stage III patients has a predictive role in OS. With regard to all stated limitations of our study, these results have potentially meaningful implications in the management of patient with advanced melanoma for whom surgical resection is considered a standard of care. These inexpensive markers of immunity could be used clinically to identify patients at higher risk of relapse who may benefit from adjuvant treatment. Full understanding of the utility of ALC and AMC in clinical practice will require a confirmatory prospective study.
